You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Gilead Sciences to Present at the Wells Fargo Securities 2013 Healthcare Conference on Tuesday, June 18
Gilead Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin’s Lymphoma
Gilead Sciences to Present at the Goldman Sachs 34th Annual Healthcare Conference on Tuesday, June 11
Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C
Gilead Sciences to Present at the Deutsche Bank 38th Annual Health Care Conference on Wednesday, May 29
European Commission Approves Stribild®, a New Single Tablet Regimen for the Treatment of HIV-1 Infection
European Medicines Agency Validates Gilead’s Marketing Application for Sofosbuvir for the Treatment of Hepatitis C
Gilead Sciences to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20
Gilead Announces Response Data from Phase 2 Study of Idelalisib for Previously Untreated Chronic Lymphocytic Leukemia
Gilead Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15
Gilead Sciences Announces First Quarter 2013 Financial Results
Gilead Reports Interim Data From Phase 2 LONESTAR Study
Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat
Gilead Sciences to Release First Quarter 2013 Financial Results on Thursday, May 2, 2013
Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C To Be Presented at 48th Annual EASL Meeting; Findings Published Online Today in The New England Journal of Medicine
Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C
Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients
European CHMP Adopts Positive Opinion for Stribild®, a Once-Daily, Integrase Inhibitor-Based, Single Tablet Regimen for the Treatment of HIV-1 Infection
Gilead’s Ranexa® Reduces Angina Frequency in Study of Chronic Angina Patients With Type 2 Diabetes
Gilead Announces Full 24-Week Phase 2 Results for Once-Daily Single Tablet HIV Regimen Containing Novel Prodrug Tenofovir Alafenamide (TAF)
Gilead Sciences to Present at the Cowen & Company 33rd Annual Health Care Conference on Monday, March 4
Gilead Sciences to Present at Two Upcoming Investor Conferences
Gilead and Teva Reach Settlement Agreement in Viread® Patent Litigation
Gilead’s Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study
Gilead Issues a Voluntary Recall of One Lot of Vistide® (Cidofovir Injection) Due to Presence of Particulate Matter
Gilead Sciences Completes Acquisition of YM BioSciences
Gilead Sciences Announces Fourth Quarter and Full Year 2012 Financial Results
Gilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir for Hepatitis C
Gilead Sciences to Release Fourth Quarter and Year End 2012 Financial Results on Monday, February 4, 2013
Gilead Initiates Phase 3 Clinical Program for Tenofovir Alafenamide, a Novel Low-Dose Prodrug for the Treatment of HIV
Gilead Provides Update on Hepatitis C Development Programs
Gilead Sciences to Present at the 31st Annual JPMorgan Healthcare Conference on Monday, January 7
2012 Interactive Annual Report